

BIOSANTE PHARMACEUTICALS INC  
Form 8-K  
May 17, 2004

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----  
FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

-----

Date of Report (Date of earliest event reported):  
MAY 17, 2004

BIOSANTE PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)

DELAWARE                                      1-31812                                      58-2301143  
(State or Other Jurisdiction      (Commission File Number)      (I.R.S. Employer  
of Incorporation)                                      Identification Number)

111 BARCLAY BOULEVARD  
LINCOLNSHIRE, ILLINOIS                                      60069  
(Address of Principal Executive Offices)                                      (Zip Code)

(847) 478-0500  
(Registrant's Telephone Number, Including Area Code)

N/A  
(Former Name or Former Address, If Changed Since Last Report)

=====

ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On May 17, 2004, BioSante Pharmaceuticals, Inc. announced its financial results for the first quarter ended March 31, 2004. Attached to this Current Report on Form 8-K as Exhibit 99.1 is a copy of BioSante Pharmaceutical's press release in connection with the announcement. The information in this report is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

by reference by any general statements by BioSante Pharmaceuticals, Inc. incorporating by reference this report or future filings into any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent BioSante Pharmaceuticals, Inc. specifically incorporates the information by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSANTE PHARMACEUTICALS, INC.

By: /s/ Phillip B. Donenberg

-----  
Phillip B. Donenberg  
Chief Financial Officer,  
Treasurer and Secretary

Dated: May 17, 2004